Long-Term Debt (Quarterly)

Long-Term Debt: The sum of all long term debt fields.

Integra LifeSciences Holdings Corporation (IART) had Long-Term Debt of $1.23B for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$382.65M
Net Income	$-25.29M
Cost of Goods Sold	$188.22M
Gross Profit	$194.43M
Operating Expenses	$398.15M
Operating Income	$-15.50M
Non-Operating Income/Expense	$-14.54M
Pre-Tax Income	$-30.04M
Normalized Pre-Tax Income	$-30.04M
Income after Taxes	$-25.29M
Income from Continuous Operations	$-25.29M
Consolidated Net Income/Loss	$-25.29M
Normalized Income after Taxes	$-25.29M
EBIT	$-15.50M
EBITDA	$23.08M
Weighted-Average Shares Outstanding (Basic)	76.46M
Weighted-Average Shares Outstanding (Diluted)	76.46M
Earnings per Share (EPS) (Basic)	$-0.33
Earnings per Share (EPS) (Diluted)	$-0.33
Balance Sheet Financials
Current Assets	$1.11B
Property, Plant, and Equipment	$422.91M
Long-Term Assets	$2.95B
Total Assets	$4.05B
Current Liabilities	$918.45M
Long-Term Debt	$1.23B
Long-Term Liabilities	$1.61B
Total Liabilities	$2.53B
Common Equity	$1.52B
Tangible Shareholders Equity	$-768.78M
Shareholders Equity	$1.52B
Common Shares Outstanding	77.71M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-11.26M
Cash Flow from Investing Activities	$-35.92M
Cash Flow from Financial Activities	$35.38M
Beginning Cash	$246.38M
End Cash	$239.10M
Increase/Decrease in Cash	$-7.27M
Stock-Based Compensation	$1.87M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.45
Debt to Equity Ratio	1.21
Gross Margin	50.81%
Operating Margin	-4.05%
EBIT Margin	-4.05%
EBITDA Margin	--
Pre-Tax Profit Margin	-7.85%
Profit Margin	-6.61%
Free Cash Flow	$-40.18M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.09
Inventory Turnover	0.42
Receiveable Turnover	1.52
Days Sales in Receivables	59.38
Return on Equity	-1.66%
Return on Tangible Equity	3.29%
Return on Assets	-0.62%
Return on Investments	-0.92%
Book Value Per Share	$19.61
Free Cash Flow per Share	$-0.53
Operating Cash Flow per Share	$-0.15

Data from Zacks Investment Research, Inc.